In a first, India to conduct experiments aboard ISS to study sustainability of life in space
NEW DELHI: India is all set to conduct the first ever biological experiment aboard the International Space Station (ISS) to study the sustainability of human life in space, ministry of science & technology announced on Thursday. The initiative comes as a part of BioE3 Biotechnology policy launched by Prime Minister Narendra Modi.
"In a historic initiative, the first of its kind ever in the world, India is set to conduct first-ever biological experiments aboard the "International Space Station" (ISS) to study the sustainability of human life in Space," science and technology minister Jitendra Singh said in a post on X.
"The unique experiments, spearheaded by the
Indian Space Research Organisation
#Isro in collaboration with the
Department of Biotechnology
#DBT, will be carried out as part of the upcoming International Space Station (ISS) mission Axiom-4, with Indian astronaut Group Captain Shubhanshu Shukla as a crew member. The DBT has undertaken this ambitious project as a sequel to the "#BioE3" Biotechnology policy launched by PM Sh @NarendraModi," he added.
The experiments led by Isro in partnership with the Department of Biotechnology (DBT) are set to take place aboard the upcoming
Axiom-4 mission
to the International Space Station, with astronaut group captain Shubhanshu Shukla among the crew, according to a statement by the department.
"This project is a joint initiative of Isro, Nasa, and DBT and aims to analyze key growth parameters and changes in transcriptomes, proteomes, and metabolomes of different algal species in space, as compared to Earth-based controls. The results will help identify the most suitable microalgal species for use in space environments, he added," the statement said.
The second experiment aboard the ISS will examine how cyanobacteria like Spirulina and Synechococcus grow and respond at the proteomic level in microgravity, using both urea- and nitrate-based nutrient media, it said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
an hour ago
- NDTV
New Images Capture Mount Etna's Massive Eruption From Space
On June 2, Mount Etna erupted, spewing hot lava down its slopes as a massive ash cloud towered above Sicily. Located on the Italian island of Sicily, Europe's highest and most active volcano sent a colossal plume of ash soaring up to 5 kilometres into the sky during the eruption. Meanwhile, a European Space Agency satellite captured the whole thing from space. Copernicus Sentinel-2C snapped dramatic photos of the eruption just minutes after it began, providing a unique perspective on the volcanic activity. The satellite, launched by the European Commission's Earth observation program in September 2024, captured striking images of Mount Etna's eruption from an altitude of 775 km. The photos reveal a dense ash plume and a pyrocumulus cloud drifting over inland Sicily, as well as active lava flows descending into the Valle del Bove. "The image here clearly depicts the lava flow and huge plume of smoke and ash. A capture from the Copernicus Sentinel-5P satellite also shows the sulphur dioxide emitted in the plume," ESA wrote while sharing the image. See the image here: 🌋 Mount Etna's latest eruption on 2 June was caught by @CopernicusEU Sentinel-2. This image shows the lava distribution from the eruption, using an infrared overlay to highlight lava flowing. — European Space Agency (@esa) June 4, 2025 As per ESA's Copernicus Sentinel-5P satellite caught the eruption using its wide swath high-resolution multispectral imager that includes 13 spectral bands for imaging Earth's vegetation and landscape. The Copernicus satellites provide critical data to experts, enabling them to monitor volcanic activity, assess hazards, support emergency responses, and track long-term landscape changes. The eruption began at 11:24 am local time on June 2, when increased pressure from hot gases inside Mount Etna led to a partial collapse of one of its craters. This triggered a pyroclastic flow, sending a dense column of ash and smoke kilometres into the atmosphere. Lava flowed in three directions but began to cool down. Pyroclastic flows are highly hazardous, reaching temperatures of up to 1,000°C and travelling at speeds of around 60 miles per hour. #Etna 2025 suite de l'éruption — 🥗Aurelien Pouzin🍯 (@aurelienpouzin) June 2, 2025 Notably, there hadn't been an eruption from Etna of this magnitude since 2014, according to the National Institute of Geophysics and Volcanology Observatory. The National Institute of Geophysics and Volcanology (INGV) had noted Mount Etna was experiencing "intense and almost continuous" strombolian explosions. According to the latest statement by INGV, the eruption activity has ceased.
Time of India
2 hours ago
- Time of India
Dr Reddy's, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global (generic name is pembrolizumab ), manufactured and marketed by Merck & Co , is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, Hyderabad-based DRL said in a statement on to certain exceptions, each party will have the right to commercialise the product traditional generics, which often face automatic patent infringement claims, biosimilars are developed more like original drugs, complete with clinical trials and patent disclosures, giving them a better chance of overcoming legal challenges. Also, Merck's core patents on pembrolizumab in the US are expected to start expiring around 2028.'This (collaboration) demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide,' Erez Israeli, chief executive of DRL, said.Róbert Wessman, chairman and CEO of Alvotech, said, 'The agreement enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide.'Keytruda is approved in the US to treat 40 cancers, unlike most medicines that treat a few indications or medical India, it is approved for use in 17 indications across 10 cancers or tumour types. Oncologists mostly prescribe it to treat certain types of lung cancers, followed by gastrointestinal cancer, triple-negative breast cancer and head and neck helps the body's immune system, which is the T-cells, to detect and fight cancer cells that hide and spread in organs.'Oncology has been a top focus therapy area for us, and this collaboration will enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ,' Israeli has been out of reach for most patients in India due to its exorbitant cost – roughly about Rs 2 lakhs for each dose. However, with Merck's patent set to expire in a few years and with Indian drug manufacturers looking to come up with more affordable versions of the drug it may play a crucial role in widening adoption across a larger cohort of patients.
India.com
3 hours ago
- India.com
India's Rs 548 crore Space Leap: Shukla rides the Falcon 9 to the ISS
On June 10, 2025, at 5:52 PM IST (8:22 AM EDT), Group Captain Shubhanshu Shukla will lift off to the International Space Station (ISS), becoming the first Indian astronaut since 1984 to undertake such a journey. As the pilot of Axiom Mission 4 (Ax-4), he will fly aboard a SpaceX Crew Dragon spacecraft, launched on a Falcon 9 rocket from NASA's Kennedy Space Center in Florida. After approximately 28 hours of travel, the crew is expected to dock with the ISS by 10:00 PM IST on June 11, 2025. Shukla joins an elite international crew: Commander Peggy Whitson (USA, Axiom Space), and Mission Specialists Sławosz Uznański-Wiśniewski (Poland, ESA) and Tibor Kapu (Hungary, Hunor Programme). The team will spend up to 14 days aboard the ISS, conducting over 60 scientific experiments from 31 countries, including seven from India, such as research on plant growth in microgravity, muscle regeneration, and tardigrade resilience. Born on October 10, 1985, in Lucknow, Shukla is a decorated Indian Air Force test pilot with over 2,000 flight hours. He has undergone rigorous astronaut training in Russia and at SpaceX facilities in the US, and will assist in spacecraft navigation, docking, and emergency procedures during the mission. But beyond his technical role, Shukla carries India's cultural pride into space—bringing along items designed by National Institute of Design (NID) students, performing yoga in microgravity, sharing Indian delicacies like mango nectar and moong dal halwa, and planning live interactions with Indian school children and possibly Prime Minister Narendra Modi. SpaceX has revolutionized space travel economics. While NASA pays around $55 million per seat under its commercial crew program, private clients like Axiom Space are charged $52–55 million per seat, excluding stay-related fees. NASA charges $35,000 per night per astronaut for use of the ISS. India's investment for Shukla's mission seat is around ₹548 crore (approximately $65 million), while the total private mission cost per astronaut can go up to $100 million, including training and logistics. In comparison, Russia's Soyuz costs around $80–86 million per seat, Boeing's Starliner costs about $90 million, and the now-retired Space Shuttle had a cost of approximately $170 million per astronaut. For reference, cargo missions on SpaceX's Dragon cost anywhere between $21,000 and $89,000 per kg, while human missions are far costlier due to added life support and safety systems. Shukla's mission is more than just a spaceflight—it's a symbol of India's return to human space exploration. He carries a special swan named 'Joy', representing wisdom (India), resilience (Poland), and grace (Hungary). The scientific experiments onboard are expected to contribute to India's ambition of establishing a space station by 2035 and support its moon mission goals set for 2047. This mission also strengthens international space ties, especially between India and the US, following commitments made during PM Modi's 2023 visit. In every sense, Group Captain Shubhanshu Shukla's journey aboard the human-rated Falcon 9 rocket is a giant leap for India—both in science and symbolism. With his successful flight, India not only rekindles its human spaceflight legacy after four decades but also sets the stage for greater roles in global space partnerships, cutting-edge research, and inspiration for the next generation of Indian scientists, engineers, and dreamers. —E.O.M (Girish Linganna is an award-winning science communicator and a Defence, Aerospace & Geopolitical is the Managing Director of ADD Engineering Components India Pvt. Ltd., a subsidiary of ADD Engineering GmbH, Germany )
